Cabotegravir Patent Expiration

Cabotegravir was first introduced by Viiv Healthcare Co in its drug Apretude on Dec 20, 2021.

Cabotegravir Patents

Given below is the list of patents protecting Cabotegravir, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Apretude	US11224597	Pharmaceutical compositions	Sep 15, 2031	Viiv Hlthcare
Apretude	US10927129	N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity	Apr 28, 2026	Viiv Hlthcare
Apretude	US8410103	(3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent	Apr 28, 2026	Viiv Hlthcare

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List